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Background: In human immunodeficiency virus (HIV)-infected patients, immune reconstitution inflammatory
syndrome (IRIS) due to nontuberculous mycobacteria (NTM) infection is one of the most difficult types of IRIS to
manage. 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (18 F-FDG PET/CT) has
been suggested as a useful tool for evaluating the inflammatory status of HIV-infected patients. We present the first
case of Mycobacterium avium complex (MAC)-associated IRIS (MAC-IRIS) that was successfully followed up using
18 F-FDG PET/CT.
Case presentation: A 44-year-old homosexual Japanese man was referred to our hospital with fever and dyspnea.
He was diagnosed with Pneumocystis jiroveci pneumonia and found to be HIV positive. After the initiation of
combined antiretroviral therapy (cART), the patient’s mediastinal and bilateral hilar lymphadenopathy gradually
enlarged, and bilateral infiltrates appeared in the upper lung fields. 18 F-FDG PET/CT was performed five months
after the initiation of cART and showed intense accumulation of fluorodeoxyglucose (FDG) corresponding to the
lesions of infiltration as well as the mediastinal and bilateral hilar lymphadenopathy. A bronchial wash culture and
pathology findings led to a diagnosis of MAC-IRIS. Anti-mycobacterial chemotherapy with rifampicin, ethambutol,
clarithromycin, and levofloxacin was started. One year after the chemotherapy was initiated, there was a significant
reduction in FDG uptake in the area of the lesions except in the mediastinal lymph node. This implied incomplete
resolution of the MAC-IRIS-related inflammation. Anti-mycobacterial chemotherapy was continued because of the
residual lesion. To date, the patient has not experienced a recurrence of MAC-IRIS, a period of nine months.
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Conclusion: We present a case of MAC-IRIS in an HIV-infected patient whose disease activity was successfully
followed up using 18 F-FDG PET/CT. Our data suggest that 18 F-FDG PET/CT is useful for evaluating the disease
activity of NTM-IRIS and assessing the appropriate duration of anti-mycobacterial chemotherapy for NTM-IRIS in
HIV-infected patients.
Keywords: Immune reconstitution inflammatory syndrome, Human immunodeficiency virus, Nontuberculous
mycobacteria, Mycobacterium avium complex, 18 F-fluorodeoxyglucose positron emission tomography/computed
tomographyBackground
Combined antiretroviral therapy (cART) targeting the
human immunodeficiency virus (HIV) has dramatically
improved the prognosis of HIV-infected patients by sup-
pressing HIV and restoring the disrupted host immune
system [1]. During host immune recovery after the initi-
ation of cART, a subset of HIV-infected patients experi-
ence a paradoxical worsening of coexisting infections or
the appearance of new diseases; this has been named the
immune reconstitution inflammatory syndrome (IRIS).
Since IRIS, a fatal complication, occurs in 13 % of HIV-
infected patients, the clinical importance of these patients
has increased in the cART era [2]. IRIS is associated with a
variety of medical conditions including cytomegalovirus ret-
initis, cryptococcal meningitis, tuberculosis (TB), progres-
sive multifocal leukoencephalopathy, and herpes zoster
infection [2]. Among these IRIS conditions, nontuberculous
mycobacteria (NTM)-associated IRIS (NTM-IRIS) is one of
the most difficult diseases to manage since it often results
in a poor prognosis, even if intensive anti-NTM chemo-
therapy is initiated [3]. A detailed clinical characterization
of NTM-IRIS should be performed to establish an appro-
priate management strategy for NTM-IRIS; however, only a
few reports have described detailed clinical findings, and
radiological findings are lacking [4].
Recently, 18 F-fluorodeoxyglucose (FDG) positron emis-
sion tomography/computed tomography (18 F-FDG PET/
CT) has been used for diagnosing fever of unknown origin
and acquired immunodeficiency syndrome (AIDS)- and
non-AIDS-related cancers in HIV-infected patients [5–7].
In addition, the methodology has been suggested as a poten-
tial tool for evaluating the responsiveness of TB infection to
anti-tuberculous therapy in HIV-infected patients [8]. How-
ever, there have been no case reports of patients with
NTM-IRIS whose disease activity was assessed using 18 F-
FDG PET/CT. Herein, we report a case of an HIV-infected
patient with Mycobacterium avium complex (MAC)-associ-
ated IRIS (MAC-IRIS) that was successfully followed up
using 18 F-FDG PET/CT.
Case presentation
A 44-year-old homosexual Japanese man was referred to
our hospital with fever and dyspnea. Pneumocystisjiroveci pneumonia (PCP) was diagnosed using a sputum
smear, and the patient was found to be positive for HIV.
At the time of the HIV/AIDS diagnosis, the patient’s
CD4-positive T cell count was 11 cells/μL, and his HIV-
RNA viral load was 2.0 × 106 copies/mL. The patient was
an ex-smoker (5 pack-years) and social drinker. Two
months after the successful treatment of PCP, chest
radiograph findings returned to almost normal (Fig. 1a),
and cART was started with emtricitabine/tenofovir
(200 mg/300 mg daily), darunavir (400 mg daily), and rito-
navir (100 mg daily). Due to the low CD4-positive T cell
count, sulfamethoxazole/trimethoprim (400 mg/80 mg
daily) and azithromycin (1000 mg weekly) were prophylac-
tically prescribed.
Five months after the initiation of the cART, a chest
radiograph displayed bilateral infiltrates of the upper
lung fields and bilateral hilar lymphadenopathy (Fig. 1b).
Consistently, a high-resolution computed tomography
(CT) scan revealed bilateral infiltrates of the upper lobe
of the lungs and mediastinal and bilateral hilar lymph-
adenopathy (Fig. 2a–2d). However, the patient did not
have any symptoms such as fever, general fatigue, or
respiratory symptoms (including cough and purulent
sputum). For further radiological investigation, 18 F-FDG
PET/CT was performed. It showed intense accumulation
of FDG corresponding to the lesions of the infiltrates as
well as the mediastinal and bilateral hilar lymphadenop-
athy (maximum standardized uptake value: 18.42; Fig. 2e
and 2f). The differential diagnosis of the lung infiltrates
and lymphadenopathy at that time included NTM-IRIS,
TB-IRIS, sarcoidosis, malignant lymphoma, fungal infec-
tion, and Kaposi’s sarcoma.
The patient was admitted to the Keio University
Hospital for further investigations. At the time of admis-
sion, vital signs and physiological examinations were
normal except for a bilateral deep cervical lymphadenop-
athy. The results of blood tests are shown in Table 1.
The patient’s white blood cell count (2900/μL) and
hemoglobin levels (12.2 g/dL) were low, while alkaline
phosphatase levels (403 IU/L) were high. The concentrations
of C-reactive protein (0.13 mg/dL), anti-glycopeptidolipid
core IgA antibody (<0.1 U/mL), angiotensin-converting
enzyme (16.2 IU/mL), and soluble interleukin-2
Fig. 1 Serial changes on chest radiograph. a Chest radiograph taken at the time of starting combined antiretroviral therapy (cART), showing
almost normal findings. b Chest radiograph taken five months after starting cART, showing infiltrates in the bilateral upper lung fields (white
arrow) and bilateral hilar lymphadenopathy (black arrow). c Chest radiograph taken one year after starting anti-mycobacterial chemotherapy,
showing slight hilar lymphadenopathy
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positive T cell count had risen to 125 cells/μL, while
the HIV-RNA viral load had decreased to undetectable
levels. A smear was negative for acid-fast bacilli. Blood
and sputum cultures were negative for bacteria and
mycobacteria. We performed an endobronchial biopsy
of the endobronchial mass and a bronchial wash of the
left upper lobe bronchus (Fig. 3a, 3b). Histological
examination of the biopsy specimen revealed granu-
lomatous change but was negative for malignancy,
human herpes virus-8, and fungi such as Aspergillus
species and Cryptococcus species. Caseating granuloma,
the typical histological finding of mycobacteria (includ-
ing Mycobacterium tuberculosis and NTM), was not
identified in the specimen. Although the smear test was
negative for mycobacteria, a bronchial wash culture
that was performed later was positive for MAC. Ac-
cordingly, the patient was diagnosed with MAC-IRIS,
and anti-MAC chemotherapy with rifampicin (450 mg
daily), ethambutol (750 mg daily), clarithromycin
(800 mg daily), and levofloxacin (500 mg daily) was
started. Since we could not exclude the possibility of
TB or TB-IRIS, we added isoniazid (300 mg per day) to
the chemotherapy regimen. We also changed the cART
regimen from darunavir and ritonavir to raltegravir to
avoid a potential drug interaction.
We did not consider using concomitant non-steroidal
anti-inflammatory drugs or steroids for two reasons: 1)
the patient was able to continue anti-mycobacterial
chemotherapy without remarkable side effects and 2) his
chest radiograph findings showed a gradual improve-
ment in the bilateral upper lung field and the hilar
lymphadenopathy. One year after the introduction of
the anti-mycobacterial chemotherapy, chest radiograph
and high-resolution CT findings showed slight hilar
lymphadenopathy (Figs. 1c, 2g, and 2h). To evaluate dis-
ease activity more precisely, 18 F-FDG PET-CT was per-
formed. It showed a marked reduction in FDG uptake,
but accumulation of FDG was still seen in a right lowerparatracheal lymph node (station #4R; maximum stan-
dardized uptake value: 6.24), implying incomplete reso-
lution of the NTM-IRIS-associated inflammation. Based
on these findings, we continued anti-mycobacterial
chemotherapy for an additional nine months to the
present date. The patient has not experienced any fur-
ther recurrence of NTM-IRIS as assessed based on his
symptoms and chest radiographs.
Conclusion
MAC infection often causes disseminated disease in
patients with AIDS. On the other hand, MAC can also
present as IRIS after the initiation of cART in HIV-
infected patients. MAC-IRIS occurs in about 3.5 % of
HIV-infected patients treated with cART, and 20 % of
MAC-IRIS is fatal [2]. No case reports have evaluated
the long-term radiological findings of MAC-IRIS.
To our knowledge, this is the first case report of an
HIV-infected patient with MAC-IRIS whose disease ac-
tivity was followed up and evaluated using 18 F-FDG
PET/CT. Although there are no established guidelines
for the management of NTM-IRIS, several approaches
have been suggested, such as the interruption of cART
and the initiation of anti-NTM chemotherapy in combin-
ation with or without non-steroidal anti-inflammatory
drugs or steroids [3]. However, since the interruption of
cART can exacerbate the immunosuppressed status in
HIV-infected patients, it is preferable to avoid choosing
the interruption of cART, if possible. In particular, the
interruption of cART can result drug-resistant HIV. In the
current case, we chose only anti-NTM chemotherapy to
avoid these risks.
It is important to evaluate whether anti-MAC chemo-
therapy for MAC-IRIS has been successful in clinical
settings. Clinicians can use 18 F-FDG PET/CT to assess
the accumulation of FDG as well as to determine the
size of a lesion to determine disease activity. Previous
studies that assessed TB disease activity in an HIV-
infected patient showed that 18 F-FDG PET/CT had a
Fig. 2 Chest computed tomography and 18 F-fluorodeoxyglucose positron emission tomography-computed tomography findings. a–d A computed
tomography scan performed five months after starting cART showed bilateral infiltrates in the upper lobes of the lungs and mediastinal and bilateral
hilar lymphadenopathy. e, f The 18 F-fluorodeoxyglucosepositron emission tomography-computed tomography (18 F-FDG PET/CT) scan performed five
months after starting cART showed intense accumulation of fluorodeoxyglucose (FDG) around the infiltrates and the mediastinal and bilateral hilar
lymphadenopathy (maximum standardized uptake value: 18.42). g, h The 18 F-fluorodeoxyglucose positron emission tomography-computed
tomography (18 F-FDG PET/CT) scan performed one year after starting anti-mycobacterial chemotherapy showed a decreased uptake of FDG
when compared to the scan performed five months after starting combined antiretroviral therapy (cART). Moreover, a reduction in FDG uptake
was observed in the area of the lesions with the exception of a right-lower paratracheal lymph node (station #4R; maximum standardized
uptake value: 6.24)
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HIV patients who responded to anti-mycobacterial chemo-
therapy from those who did not [8, 9]. Since a high FDG
accumulation has also been reported in the lesions of
patients with non-HIV MAC infections, it is reasonable to
consider utilizing 18 F-FDG PET/CT in MAC-infected HIV
patients [10].
The usefulness of serological inflammatory markers
for evaluating the disease activity of mycobacterium-
associated IRIS in HIV-infected patients remains contro-
versial. In fact, C-reactive protein levels, white blood cellcounts, and erythrocyte sedimentation rates were not
elevated in the present case.
The optimal duration of anti-mycobacterial chemo-
therapy in regards to the disease activity of NTM-IRIS
remains unknown [11]. In particular, patients with
MAC-IRIS tend to relapse frequently after treatments
such as anti-mycobacterial chemotherapy or steroids [3].
18 F-FDG PET/CT imaging may help determine the ap-
propriate duration of anti-mycobacterial chemotherapy.
In the present case, considering the residual inflamma-
tion observed in 18 F-FDG PET/CT, we continued the
Table 1 Laboratory findings on admission
Complete blood count
White blood cells 2900/μL
Band cells + segmented cells 63.8 %
Lymphocytes 24.9 %
Monocytes 7.7 %
Eosinophil granulocytes 3.2 %
Basophil granulocytes 0.4 %
Hemoglobin 12.2 g/dL
Mean corpuscular volume 77/fL
Platelets 16.9 × 104/μL
Biochemistry
Total protein 6.4 g/dL
Albumin 4.2 g/dL
Total bilirubin 0.3 mg/dL
Aspartate transaminase 18 IU/L
Alanine transaminase 13 IU/L
Lactate dehydrogenase 184 IU/L





Alkaline phosphatase 403 IU/L
Serological studies
C-reactive protein 0.13 mg/dL
β-D-glucan 4.4 pg/mL
Aspergillus antigen 0.1 COI
Cryptococcus antigen 0.0 COI
QuantiFERON® TB Gold test Negative
Anti-glycopeptidolipid core IgA antibody <0.1 U/mL
Angiotensin-converting enzyme 16.2 IU/mL
Soluble interleukin-2 receptor 482 U/mL
CD4 positive T cells 125 counts/μL
HIV RNA viral load <20 copies/mL
Fig. 3 Chest computed tomography and bronchoscopy findings.
a Computed tomography scan performed five months after starting
cART showing the endobronchial mass (arrow). b Bronchoscopy
showing the endobronchial mass in the left upper lobe bronchus
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Demura et al., a maximum standardized uptake value
greater than 4.0 is generally compatible with highly active
mycobacterial granuloma lesions. Since the maximum
standardized uptake value was still 6.24 one year after
introducing anti-mycobacterial chemotherapy, it was con-
tinued [12]. This treatment strategy could contribute to
preventing the patient’s relapse with MAC-IRIS.
The use of 18 F-FDG PET/CT for assessing disease
activity of MAC in HIV-infected patients has several
limitations. First, the possibility of malignancy should be
considered, since there has been an increase in bothAIDS- and non-AIDS-related cancers in HIV-infected
patients. The maximum standardized uptake of FDG
cannot differentiate malignancy from other inflamma-
tory diseases [13]. Therefore, pathology and culture re-
sults remain important for an accurate diagnosis. In the
case presented herein, sputum and gastric fluid samples
were negative for acid-fast bacteria, except for the posi-
tive culture from the bronchial wash fluid, although the
culture tests were repeated several times. We speculate
that there was only a small amount of MAC in the le-
sion. Thus, the culture of the bronchial wash fluid is es-
sential for the diagnosis of MAC-associated lung disease.
FDG uptake can have false positive results in an HIV
patient with poor virus control, because areas of HIV
replication in lymphoid tissue can contribute to FDG
accumulation in the tissue [14]. Therefore, assessment of
FDG accumulation should be undertaken with great
care, particularly in cases of HIV with uncontrolled HIV
RNA levels.
In conclusion, 18 F-FDG PET/CT can be useful for
evaluating NTM-IRIS disease activity and assessing the
appropriate duration of anti-mycobacterial chemother-
apy in HIV-infected patients with NTM-IRIS.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by this journal.
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